Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies.
Hegde A, Andreev-Drakhlin AY, Roszik J, Huang L, Liu S, Hess K, Cabanillas M, Hu MI, Busaidy NL, Sherman SI, Dadu R, Grubbs EG, Ali SM, Lee J, Elamin YY, Simon GR, Blumenschein GR Jr, Papadimitrakopoulou VA, Hong D, Meric-Bernstam F, Heymach J, Subbiah V.
Hegde A, et al. Among authors: dadu r.
ESMO Open. 2020 Oct;5(5):e000799. doi: 10.1136/esmoopen-2020-000799.
ESMO Open. 2020.
PMID: 33097651
Free PMC article.
Clinical Trial.